Heart failure & cardiomyopathiesRandomised controlled trial
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction
- Randomised controlled trial
- double-blind
- placebo-controlled
Authors' conclusion
This randomized, double-blind, placebo-controlled trial demonstrates that GH replacement therapy in HFrEF patients with GHD improves exercise performance, and left ventricular and right ventricular structure and function, leading to an amelioration of clinical status and health-related quality of life.
Study context
- Population
- Patients with heart failure and reduced ejection fraction (HFrEF) (NYHA class I/II/III) and concomitant growth hormone deficiency45 completed
- Participants
- 64 patients
- Comparison
- Growth hormone (GH) replacement therapy vs placebo, on top of background therapy
- GHn = 30
- Placebon = 34reference
- Primary endpoint
- Peak oxygen consumption (VO2)
- Follow-up
- 1 year
Primary result
As reported in the abstract
Peak VO2 in GH improved from 12.8 ± 3.4 mL/kg/min to 15.5 ± 3.15 mL/kg/min
P < 0.01
Secondary outcomes
Other cardiopulmonary exercise test parameters (peak workload, VO2 at aerobic threshold, O2 pulse, VE/VCO2 slope)
- Improved
- P < 0.05
6-minute walking test distance
- Increased
- P < 0.05
Handgrip strength
- Increased
- P < 0.01
RV function (TAPSE and TAPSE/pulmonary artery systolic pressure ratio)
- GH improved RV function
- P < 0.01
NYHA functional class
- Amelioration of clinical status
- P < 0.05
Health-related quality of life (Minnesota Living With Heart Failure Questionnaire)
- Improved
- P < 0.05
NT-proBNP
- Significant decrease
- P < 0.05
Original publication
Summarised from the published abstract; every number is checked against it